CN111743583A - Autologous cell transplantation method - Google Patents
Autologous cell transplantation method Download PDFInfo
- Publication number
- CN111743583A CN111743583A CN202010633384.6A CN202010633384A CN111743583A CN 111743583 A CN111743583 A CN 111743583A CN 202010633384 A CN202010633384 A CN 202010633384A CN 111743583 A CN111743583 A CN 111743583A
- Authority
- CN
- China
- Prior art keywords
- injection
- wrinkles
- scars
- epidermis
- autologous
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract description 23
- 238000002054 transplantation Methods 0.000 title claims abstract description 19
- 230000037303 wrinkles Effects 0.000 claims abstract description 51
- 238000002347 injection Methods 0.000 claims abstract description 35
- 239000007924 injection Substances 0.000 claims abstract description 35
- 210000003491 skin Anatomy 0.000 claims abstract description 25
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 22
- 210000002615 epidermis Anatomy 0.000 claims abstract description 21
- 210000001519 tissue Anatomy 0.000 claims abstract description 18
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 claims abstract description 16
- 229960004194 lidocaine Drugs 0.000 claims abstract description 16
- 210000004207 dermis Anatomy 0.000 claims abstract description 15
- 239000003761 preservation solution Substances 0.000 claims abstract description 11
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 claims abstract description 6
- 229930182837 (R)-adrenaline Natural products 0.000 claims abstract description 6
- 239000000427 antigen Substances 0.000 claims abstract description 6
- 102000036639 antigens Human genes 0.000 claims abstract description 6
- 108091007433 antigens Proteins 0.000 claims abstract description 6
- 229960005139 epinephrine Drugs 0.000 claims abstract description 6
- 208000002672 hepatitis B Diseases 0.000 claims abstract description 6
- 230000003907 kidney function Effects 0.000 claims abstract description 6
- 230000003908 liver function Effects 0.000 claims abstract description 6
- 230000001954 sterilising effect Effects 0.000 claims abstract description 6
- 231100000241 scar Toxicity 0.000 claims description 30
- 208000032544 Cicatrix Diseases 0.000 claims description 25
- 230000037387 scars Effects 0.000 claims description 25
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 20
- 239000006285 cell suspension Substances 0.000 claims description 12
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 10
- 229930003268 Vitamin C Natural products 0.000 claims description 10
- 238000012360 testing method Methods 0.000 claims description 10
- 235000019154 vitamin C Nutrition 0.000 claims description 10
- 239000011718 vitamin C Substances 0.000 claims description 10
- 230000035755 proliferation Effects 0.000 claims description 6
- 206010002091 Anaesthesia Diseases 0.000 claims description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 5
- 230000037005 anaesthesia Effects 0.000 claims description 5
- 239000006071 cream Substances 0.000 claims description 5
- 230000000249 desinfective effect Effects 0.000 claims description 5
- 230000008034 disappearance Effects 0.000 claims description 5
- 239000002674 ointment Substances 0.000 claims description 5
- 229960001807 prilocaine Drugs 0.000 claims description 5
- MVFGUOIZUNYYSO-UHFFFAOYSA-N prilocaine Chemical compound CCCNC(C)C(=O)NC1=CC=CC=C1C MVFGUOIZUNYYSO-UHFFFAOYSA-N 0.000 claims description 5
- 238000000926 separation method Methods 0.000 claims description 5
- 238000009958 sewing Methods 0.000 claims description 5
- 239000000741 silica gel Substances 0.000 claims description 5
- 229910002027 silica gel Inorganic materials 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 2
- 230000001413 cellular effect Effects 0.000 claims 2
- 239000012530 fluid Substances 0.000 claims 2
- 238000009534 blood test Methods 0.000 claims 1
- 238000009535 clinical urine test Methods 0.000 claims 1
- 238000002563 stool test Methods 0.000 claims 1
- 210000004027 cell Anatomy 0.000 abstract description 30
- 210000002950 fibroblast Anatomy 0.000 abstract description 24
- 230000003796 beauty Effects 0.000 abstract description 11
- 102000008186 Collagen Human genes 0.000 abstract description 8
- 108010035532 Collagen Proteins 0.000 abstract description 8
- 229920001436 collagen Polymers 0.000 abstract description 8
- 241000725303 Human immunodeficiency virus Species 0.000 abstract description 5
- 239000008280 blood Substances 0.000 abstract description 5
- 210000004369 blood Anatomy 0.000 abstract description 5
- 210000002700 urine Anatomy 0.000 abstract description 5
- 230000003248 secreting effect Effects 0.000 abstract description 4
- 102000016942 Elastin Human genes 0.000 abstract description 3
- 108010014258 Elastin Proteins 0.000 abstract description 3
- 229920002549 elastin Polymers 0.000 abstract description 3
- 238000000338 in vitro Methods 0.000 abstract description 3
- 231100000862 numbness Toxicity 0.000 abstract description 3
- 239000002243 precursor Substances 0.000 abstract description 3
- 230000008961 swelling Effects 0.000 abstract description 3
- 238000002691 topical anesthesia Methods 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 13
- 239000007788 liquid Substances 0.000 description 8
- 230000002500 effect on skin Effects 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 210000001671 embryonic stem cell Anatomy 0.000 description 3
- 238000004321 preservation Methods 0.000 description 3
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 2
- 108030001720 Bontoxilysin Proteins 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 229940053031 botulinum toxin Drugs 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 210000002744 extracellular matrix Anatomy 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 229920002674 hyaluronan Polymers 0.000 description 2
- 229960003160 hyaluronic acid Drugs 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- RUXQWZJWMCHCHH-IZZDOVSWSA-N [(e)-1-pyridin-2-ylethylideneamino]urea Chemical compound NC(=O)N\N=C(/C)C1=CC=CC=N1 RUXQWZJWMCHCHH-IZZDOVSWSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- -1 embryonic stem cells Proteins 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 230000037314 wound repair Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B2017/00743—Type of operation; Specification of treatment sites
- A61B2017/00747—Dermatology
- A61B2017/00761—Removing layer of skin tissue, e.g. wrinkles, scars or cancerous tissue
Abstract
The invention relates to the technical field of cell transplantation and discloses an autologous cell transplantation method, which comprises the following steps: 1) before operation, patients need to be examined by blood routine, urine routine, stool routine, electrocardiogram, liver function, kidney function, AIDS virus, hepatitis B surface antigen and the like; 2) sterilizing skin with 75% ethanol from the back of ear or inner side of upper arm in sterile room, performing topical anesthesia with 1% lidocaine and 1/100000 epinephrine, collecting epidermis and dermis of l cm × l cm, placing in tissue preservation solution prepared in advance, and covering the wound with a needle. The autologous cell transplantation method is characterized in that fibroblasts capable of secreting autologous collagen and elastin are cultured by obtaining fibroblast precursor cells in autologous skin tissues of a beauty patient, a large amount of fibroblasts are amplified in vitro and then are infused back to wrinkle parts of the beauty patient, and few patients have slight swelling, numbness and other feelings at injection parts within 24 hours after operation and naturally disappear without treatment.
Description
Technical Field
The invention relates to the technical field of cell transplantation, in particular to an autologous cell transplantation method.
Background
The current development trend of cosmetology is towards the development of simplicity, minimal invasion and safety, the treatment of facial aging is also converted from the past surgical treatment to the injection treatment of biomedical preparations, the main biological injection preparations comprise collagen, hyaluronic acid, embryonic stem cells, botulinum toxin and the like, except that the botulinum toxin acts on dynamic wrinkles of the face, the rest is used for treating fine wrinkles caused by skin aging, wherein collagen and hyaluronic acid are main components of extracellular matrix of dermal tissue, has the main biological substitution effect in the skin, supplements the gradually reduced dermis and extracellular matrix in the aged skin, has the characteristics of obvious wrinkle removing effect and quick response, however, most of the preparations are foreign or xenogenic components, so that the possibility of immunological rejection and anaphylactic reaction exists, and the biological metabolism makes it degrade quickly, and the short duration of effect is the main disadvantage of the products.
The embryonic stem cell is also a biological beauty product developed in recent years, which has the characteristics of continuous biological beauty effect and immunogenicity, but the embryonic stem cell has limited source, difficult purification and preservation and can not completely eliminate the disadvantage that the immune reaction is the defect, Chinese patent CN 101033462B discloses a preparation method of dermal fibroblast clone, the dermal fibroblast in the method can be used for preparing bone graft, cartilage graft, fat graft, tendon graft and skin graft or injected on the body surface for wrinkle removal and beauty treatment, the fibroblast is the main cell component of the skin, the fibroblast has the functions of synthesizing and secreting three fiber APSC multipotential cells and matrix, and has very important function in the processes of interstitial renewal and wound repair, the skin of a human body is divided into two layers of epidermis and dermis, and the dermal tissue forms the bracket structure of the skin, the main component influencing the elasticity and toughness of the skin, the dermis is mainly composed of collagen, the thickness and the elasticity of skin tissues are directly influenced by the amount of the collagen, fibroblasts in the dermis tissues and the collagen secreted by the fibroblasts are reduced along with the aging of the skin, the main reason why various wrinkles appear on the skin is provided, the sufficient number of fibroblasts provided for the skin is a main mechanism for carrying out biological wrinkle removal by using fibroblast precursor cells, the proliferation and the secretion activity of mature fibroblasts are limited, research shows that the fibroblasts are developed from the maturation of the fibroblast precursor cells, the existing fibroblast transplantation method on the market has a common wrinkle removal effect, the treatment effect needs to be improved, and the autologous cell transplantation method is provided for solving the problems.
Disclosure of Invention
Technical problem to be solved
Aiming at the defects of the prior art, the invention provides an autologous cell transplantation method, which has the advantage of good wrinkle removal effect and solves the problems that the existing fibroblast transplantation method on the market has common wrinkle removal effect and the treatment effect needs to be improved.
(II) technical scheme
The technical problem to be solved by the invention is to provide an autologous cell transplantation method, which comprises the following steps:
1) relevant examination should be performed before the operation of the patient;
2) sterilizing skin with 75% ethanol from the back of ear or inner side of upper arm in sterile room, performing local surface anesthesia with 1% lidocaine and 1/100000 epinephrine, collecting epidermis and dermis of lcm × lcm, placing in tissue preservation solution prepared in advance, and sewing a needle at wound part to cover with band-aid;
3) immediately placing the specimen into tissue preservation solution after taking the specimen, preserving the specimen in an incubator at 2-10 ℃, carrying out cell separation and proliferation culture within 6-8h, and inspecting to be qualified;
4) at the sixth week of culture, o.1ml of the cell suspension was subjected to a skin test on the subject to ensure no immune rejection;
5) taking 2-4ml of cell suspension for intradermal injection in the seventh week, injecting by using a 3ml injector and a 4.5-gauge needle with the length of 2.2cm, disinfecting a wrinkle part or a scar part by using 75% ethanol, locally injecting 1% lidocaine, or anesthetizing the epidermis by using 2.5% lidocaine and 2.5% prilocaine ointment, and externally applying the mixture for 2-4h by using an ice bag after the injection is finished;
6) the second injection is carried out after 2 weeks, and the third injection is needed for large wrinkles and scars;
7) after operation, the vitamin C is orally taken, 400mg is taken once, three times a day, or a face cream containing the vitamin C is locally worn, about 6-12 months, the follow-up is carried out 3-6 months after the operation, the disappearance condition of wrinkles or scars is observed, and 10 pictures are taken or video is carried out each time under different light rays and different angles;
8) wrinkles and scars were measured using a silica gel wrinkle model to observe and evaluate the difference in wrinkles and scars between patients before and 6 months after treatment.
Preferably, the relevant tests are tests of blood routine, urine routine, stool routine, electrocardiogram, liver function, kidney function, AIDS virus and hepatitis B surface antigen.
Preferably, the cell sap is injected downwards into the upper layer and the lower layer of the dermis layer by adopting a multipoint inclined plane, the epidermis of an injection part is tightened to whiten the cell sap during injection, and all wrinkles or scars are injected.
(III) advantageous effects
Compared with the prior art, the invention provides an autologous cell transplantation method, which has the following beneficial effects:
the autologous cell transplantation method is characterized in that fibroblasts in autologous skin tissues of a beauty patient are obtained, the fibroblasts capable of secreting autologous collagen and elastin are cultured, a large amount of fibroblasts are amplified in vitro and then are returned to wrinkle parts of the beauty patient, few patients have slight swelling, numbness and other feelings at the injection parts within 24 hours after operation, the fibroblasts naturally disappear without treatment, the short-term satisfaction rate of the beauty patient on the wrinkle removing effect is 92%, the long-term satisfaction rate is 70%, wrinkles are obviously improved, and the whole technology and the method are reasonable, efficient, simple, convenient and practical.
Detailed Description
The technical solutions in the embodiments of the present invention will be clearly and completely described below with reference to the embodiments of the present invention, and it is obvious that the described embodiments are only a part of the embodiments of the present invention, and not all of the embodiments. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
The first embodiment is as follows: an autologous cell transplantation method, comprising the steps of:
1) before operation, patients need to be examined by blood routine, urine routine, stool routine, electrocardiogram, liver function, kidney function, AIDS virus, hepatitis B surface antigen and the like;
2) sterilizing skin with 75% ethanol from the back of ear or inner side of upper arm in sterile room, performing local surface anesthesia with 1% lidocaine and 1/100000 epinephrine, collecting epidermis and dermis of lcm × lcm, placing in tissue preservation solution prepared in advance, and sewing a needle at wound part to cover with band-aid;
3) immediately placing the specimen in tissue preservation solution after taking the specimen, preserving the specimen in an incubator at 2 ℃, carrying out cell separation and proliferation culture within 6 hours, and inspecting to be qualified;
4) at the sixth week of culture, o.1ml of the cell suspension was subjected to a skin test on the subject to ensure no immune rejection;
5) taking 2ml of cell suspension liquid for intradermal injection in the seventh week, injecting the cell suspension liquid by using a 3ml injector and a 4.5-gauge needle with the length of 2.2cm, disinfecting a wrinkle part or a scar part by using 75% ethanol, locally injecting 1% lidocaine or anesthetizing the epidermis by using 2.5% lidocaine and 2.5% prilocaine ointment, injecting cell liquid into the upper layer and the lower layer of the dermis by adopting a multipoint inclined plane, tightening the epidermis of an injection part during injection to whiten the epidermis, completely injecting wrinkles or scars, and externally applying the cell liquid for 2 hours by using an ice bag after injection;
6) the second injection is carried out after 2 weeks, and the third injection is needed for large wrinkles and scars;
7) after operation, vitamin C is orally taken, 300mg each time, three times a day, or a face cream containing the vitamin C is locally worn, the follow-up is carried out for about 6 months and 3 months after the operation, the disappearance condition of wrinkles or scars is observed, and 10 pictures are taken or recorded under different light rays and different angles each time;
8) wrinkles and scars were measured using a silica gel wrinkle model to observe and evaluate the difference in wrinkles and scars between patients before and 6 months after treatment.
Example two: an autologous cell transplantation method, comprising the steps of:
1) before operation, patients need to be examined by blood routine, urine routine, stool routine, electrocardiogram, liver function, kidney function, AIDS virus, hepatitis B surface antigen and the like;
2) sterilizing skin with 75% ethanol from the back of ear or inner side of upper arm in sterile room, performing local surface anesthesia with 1% lidocaine and 1/100000 epinephrine, collecting epidermis and dermis of lcm × lcm, placing in tissue preservation solution prepared in advance, and sewing a needle at wound part to cover with band-aid;
3) immediately placing the specimen in tissue preservation solution after taking the specimen, preserving the specimen in a heat preservation box at 10 ℃, carrying out cell separation and proliferation culture within 8 hours, and inspecting to be qualified;
4) at the sixth week of culture, o.1ml of the cell suspension was subjected to a skin test on the subject to ensure no immune rejection;
5) taking 4ml of cell suspension for intradermal injection in the seventh week, injecting by using a 3ml injector and a 4.5-gauge needle with the length of 2.2cm, disinfecting a wrinkle part or a scar part by using 75% ethanol, locally injecting 1% lidocaine or anesthetizing the epidermis by using 2.5% lidocaine and 2.5% prilocaine ointment, injecting cell sap downwards into the upper layer and the lower layer of the dermis by adopting a multipoint inclined plane, tightening the epidermis of an injection part during injection to whiten the epidermis, completely injecting wrinkles or scars, and externally applying for 4 hours by using an ice bag after injection;
6) the second injection is carried out after 2 weeks, and the third injection is needed for large wrinkles and scars;
7) orally taking vitamin C after operation, 400mg each time, three times a day, or locally applying a face cream containing vitamin C, performing follow-up for about 12 months, performing follow-up for 6 months after operation, observing the disappearance condition of wrinkles or scars, and taking 10 pictures or recording video under different light rays and different angles each time;
8) wrinkles and scars were measured using a silica gel wrinkle model to observe and evaluate the difference in wrinkles and scars between patients before and 6 months after treatment.
Example three: an autologous cell transplantation method, comprising the steps of:
1) before operation, patients need to be examined by blood routine, urine routine, stool routine, electrocardiogram, liver function, kidney function, AIDS virus, hepatitis B surface antigen and the like;
2) sterilizing skin with 75% ethanol from the back of ear or inner side of upper arm in sterile room, performing local surface anesthesia with 1% lidocaine and 1/100000 epinephrine, collecting epidermis and dermis of lcm × lcm, placing in tissue preservation solution prepared in advance, and sewing a needle at wound part to cover with band-aid;
3) immediately placing the specimen in tissue preservation solution after taking the specimen, preserving the specimen in a heat preservation box at 6 ℃, carrying out cell separation and proliferation culture within 7h, and inspecting to be qualified;
4) at the sixth week of culture, o.1ml of the cell suspension was subjected to a skin test on the subject to ensure no immune rejection;
5) taking 3ml of cell suspension liquid for intradermal injection in the seventh week, injecting the cell suspension liquid by using a 3ml injector and a 4.5-gauge needle with the length of 2.2cm, disinfecting a wrinkle part or a scar part by using 75% ethanol, locally injecting 1% lidocaine or anesthetizing the epidermis by using 2.5% lidocaine and 2.5% prilocaine ointment, injecting cell liquid into the upper layer and the lower layer of the dermis by adopting a multipoint inclined plane, tightening the epidermis of an injection part during injection to whiten the epidermis, completely injecting wrinkles or scars, and externally applying the cell liquid for 3 hours by using an ice bag after injection;
6) the second injection is carried out after 2 weeks, and the third injection is needed for large wrinkles and scars;
7) orally taking vitamin C after operation, 350mg each time, three times a day, or locally applying a face cream containing vitamin C, performing follow-up for about 9 months and 4 months after operation, observing the disappearance condition of wrinkles or scars, and taking 10 pictures or recording under different light rays and different angles each time;
8) wrinkles and scars were measured using a silica gel wrinkle model to observe and evaluate the difference in wrinkles and scars between patients before and 6 months after treatment.
The invention has the beneficial effects that: the autologous cell transplantation method is characterized in that fibroblasts in autologous skin tissues of a beauty patient are obtained, the fibroblasts capable of secreting autologous collagen and elastin are cultured, a large amount of fibroblasts are amplified in vitro and then are returned to wrinkle parts of the beauty patient, few patients have slight swelling, numbness and other feelings at the injection parts within 24 hours after operation, the fibroblasts naturally disappear without treatment, the short-term satisfaction rate of the beauty patient on the wrinkle removing effect is 92%, the long-term satisfaction rate is 70%, wrinkles are obviously improved, and the whole technology and the method are reasonable, efficient, simple, convenient and practical.
Although embodiments of the present invention have been shown and described, it will be appreciated by those skilled in the art that changes, modifications, substitutions and alterations can be made in these embodiments without departing from the principles and spirit of the invention, the scope of which is defined in the appended claims and their equivalents.
Claims (3)
1. An autologous cell transplantation method, comprising the steps of:
1) relevant examination should be performed before the operation of the patient;
2) sterilizing skin with 75% ethanol from the back of ear or inner side of upper arm in sterile room, performing local surface anesthesia with 1% lidocaine and 1/100000 epinephrine, collecting epidermis and dermis of lcm × lcm, placing in tissue preservation solution prepared in advance, and sewing a needle at wound part to cover with band-aid;
3) immediately placing the specimen into tissue preservation solution after taking the specimen, preserving the specimen in an incubator at 2-10 ℃, carrying out cell separation and proliferation culture within 6-8h, and inspecting to be qualified;
4) at the sixth week of culture, o.1ml of the cell suspension was subjected to a skin test on the subject to ensure no immune rejection;
5) taking 2-4ml of cell suspension for intradermal injection in the seventh week, injecting by using a 3ml injector and a 4.5-gauge needle with the length of 2.2cm, disinfecting a wrinkle part or a scar part by using 75% ethanol, locally injecting 1% lidocaine, or anesthetizing the epidermis by using 2.5% lidocaine and 2.5% prilocaine ointment, and externally applying the mixture for 2-4h by using an ice bag after the injection is finished;
6) the second injection is carried out after 2 weeks, and the third injection is needed for large wrinkles and scars;
7) after operation, the vitamin C is orally taken, 400mg is taken once, three times a day, or a face cream containing the vitamin C is locally worn, about 6-12 months, the follow-up is carried out 3-6 months after the operation, the disappearance condition of wrinkles or scars is observed, and 10 pictures are taken or video is carried out each time under different light rays and different angles;
8) wrinkles and scars were measured using a silica gel wrinkle model to observe and evaluate the difference in wrinkles and scars between patients before and 6 months after treatment.
2. The method of claim 1, wherein the relevant tests are blood tests, urine tests, stool tests, electrocardiogram tests, liver functions, kidney functions, HIV tests, and hepatitis B surface antigens.
3. The method of claim 1, wherein the cellular fluid is injected into the upper and lower layers of the dermis layer by using a multi-point inclined plane, and the injection is performed by tightening the epidermis of the injection part to whiten the epidermis and injecting the whole amount of the injected cellular fluid into wrinkles or scars.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010633384.6A CN111743583A (en) | 2020-07-02 | 2020-07-02 | Autologous cell transplantation method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010633384.6A CN111743583A (en) | 2020-07-02 | 2020-07-02 | Autologous cell transplantation method |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111743583A true CN111743583A (en) | 2020-10-09 |
Family
ID=72679052
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010633384.6A Pending CN111743583A (en) | 2020-07-02 | 2020-07-02 | Autologous cell transplantation method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111743583A (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005035739A1 (en) * | 2003-10-14 | 2005-04-21 | Kohji Nishida | Regeneration treatment system |
| CN1793341A (en) * | 2005-11-03 | 2006-06-28 | 毛曦 | Process for preparing self-fibroblast by skin prefibroblast |
| CN101306208A (en) * | 2007-05-18 | 2008-11-19 | 赵紫电 | Human liquid state derma preparation for injection and its preparation method |
| US20160003856A1 (en) * | 2013-02-27 | 2016-01-07 | Alcyomics Ltd | Skin model |
-
2020
- 2020-07-02 CN CN202010633384.6A patent/CN111743583A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005035739A1 (en) * | 2003-10-14 | 2005-04-21 | Kohji Nishida | Regeneration treatment system |
| CN1793341A (en) * | 2005-11-03 | 2006-06-28 | 毛曦 | Process for preparing self-fibroblast by skin prefibroblast |
| CN101306208A (en) * | 2007-05-18 | 2008-11-19 | 赵紫电 | Human liquid state derma preparation for injection and its preparation method |
| US20160003856A1 (en) * | 2013-02-27 | 2016-01-07 | Alcyomics Ltd | Skin model |
Non-Patent Citations (1)
| Title |
|---|
| 齐向东等: "微创美容外科学", 浙江科学出版社, pages: 473 - 474 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Narita et al. | Sequential scalp assessment in hair regeneration therapy using an adipose-derived stem cell–conditioned medium | |
| JP6309268B2 (en) | Dosage unit formulation of autologous dermal fibroblasts | |
| CN112336749B (en) | Stem cell exosome microneedle patch for removing freckles and wrinkles and preparation method thereof | |
| KR20070122316A (en) | Soft tissue filler composition for injection and preparation method thereof | |
| Xu et al. | Autologous chyle fat grafting for the treatment of hypertrophic scars and scar-related conditions | |
| CN103908424A (en) | Beautifying and nursing essence and preparation method thereof | |
| Limat et al. | Organotypic cultures of autologous hair follicle keratinocytes for the treatment of recurrent leg ulcers | |
| CN105013019A (en) | Tissue engineering full-layer skin and preparing method thereof | |
| CN110478306A (en) | Facial mask of the culture supernatant containing placenta mesenchyma stem cell and preparation method thereof | |
| CN107550846A (en) | A kind of Stem Cell Activity compound formulation for beauty and skin care and preparation method thereof | |
| CN102233144A (en) | Method for implementing subcutaneous tissue regeneration by using tissue engineering technology | |
| CN114259419B (en) | Compound composition containing recombinant collagen and preparation method and application thereof | |
| Pan et al. | A long-term follow-up study of acellular dermal matrix with thin autograft in burns patients | |
| CN106344435A (en) | Skin protection cream capable of eliminating striae gravidarum | |
| RU2281776C1 (en) | Biotransplant and method for correction of soft tissue defect, method for preparing biotransplant | |
| CN111743583A (en) | Autologous cell transplantation method | |
| Dagher et al. | The self-assembled skin substitute history: successes, challenges, and current treatment indications | |
| CN111097041A (en) | Preparation method of mixed solution for repairing striae gravidarum by using mesenchymal stem cell culture medium in combination with fibronectin | |
| CN109646459A (en) | A kind of water optoinjection instrument injection umbilical cord mesenchymal stem cells preparation and its application | |
| US20220331367A1 (en) | Pharmaceutical composition for use in improving quality of scalp or skin, wound healing, or improving quality of hair | |
| CN107519126B (en) | Umbilical cord stem cell wrinkle removing agent and preparation method thereof | |
| CN102552323A (en) | Medicine for accelerating skin repair and regeneration, preparation method thereof and application thereof | |
| RU2380106C1 (en) | Method for correction of age-related skin changes | |
| CN112852724B (en) | Beauty composition containing stem cell active factor and preparation method and application thereof | |
| CN115554478A (en) | Autologous living cell preparation for biological tissue repair and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB02 | Change of applicant information | ||
| CB02 | Change of applicant information |
Address after: No. 53, Changyi Road, Wuhou District, Chengdu, Sichuan 610000 Applicant after: Chengdu Enxi Medical Management Group Co.,Ltd. Address before: No.203, 2nd floor, building 1, No.91 Shengfeng Road, Wuhou District, Chengdu, Sichuan 610000 Applicant before: Chengdu Enxi Medical Management Co.,Ltd. |
|
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20201009 |